Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed
posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of
intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intrathecal trastuzumab in
combination with subcutaneous (subQ) Granulocyte-macrophage colony-stimulating factor
(GM-CSF) in children with relapsed PFEPN